细胞治疗 z-bio 2025-07-18 2379

　　On July 15, 2025, Drimmunity/Tcelltech announced that it had completed a Series B financing of nearly US$40 million. This round of financing was led by Guotou Investment Merchants, followed by a well-known insurance fund and Hetang Venture Capital, and received strong support from institutions such as Xingye Guoxin Asset Management and Fuzhou Mindu Talent Fund. Chenglin Capital serves as the exclusive financial advisor for this financing.

　　The funds raised in this round will be mainly used to support the Sino-US clinical development of the company's core pipeline cell therapy drug TX-103, the research and development of other pipeline projects, global team expansion, and accelerating the company's international strategic layout and promoting BD cooperation.

　　TX-103 is the world's first B7-H3 CAR-T cell therapy product to enter the registered clinical trials and conduct international clinical trials, targeting solid tumors such as recurrent glioblastoma (rGBM). Glioblastoma (GBM) is the most common primary intracranial malignant tumor. The number of new patients in China and the United States is about 45,000 and 11,000 respectively. Almost all patients relapse after first-line standard treatment. The median survival (mOS) of relapsed patients is only 6-8 months, and it is more aggressive after relapse. There is a lack of effective post-line treatment methods, and there is a huge unmet clinical need.

　　TX-103 has shown excellent efficacy and safety in early clinical trials, which can significantly prolong mOS in rGBM patients, significantly improve the survival rate in one year, and is well tolerated. It is expected to break through the bottleneck of existing therapies for treatment. Global Phase I clinical trials are currently being carried out.

　　In addition, based on the founding team's deep accumulation in oncology immunology and global leadership, Tuoxin Tiancheng is simultaneously developing the next generation of universal/in vivo cell therapy and T cell adapter platforms, striving to build a global leading solid tumor immunotherapy platform company.

　　The founder of the company said: "I sincerely thank the new investors such as the leading investment firm Guotou Investment and Follow-up Investment Firm Hetang Venture Capital, as well as the existing shareholders for their consistent trust and support. This round of financing will effectively accelerate the company's development and inject strong impetus into the research and development of a variety of innovative immunotherapy and multiple pipelines. We will continue to uphold our original intention and be committed to providing cancer patients with specific high clinical value treatment solutions."